TCT briefs: Xience V outperforms Taxus at 2 years, ACC to co-sponsor TCT 2011

In addition to the PARTNER trial, newsworthy events from TCT on Thursday include the presentation of two trials showing the long-term superiority of the Xience V over Taxus and the surprising announcement that the ACC would be a co-sponsor of TCT 2011.

Two large trials presented at TCT continue to demonstrate the long-term superiority of the everolimus-eluting stent (EES) over the paclitaxel-eluting stent (PES).

Gregg Stone presented two-year outcomes from more than 3500 patients randomized in the SPIRIT IV trial to either the Xience V or the Taxus stents. At two years, the rate of target lesion failure — defined as cardiac death, target vessel MI, or ischemia-driven target lesion revascularization — was 9.9% in the Taxus group compared to 6.9% in the Xience V group (p<0.003). The rate of stent thrombosis was 1.25% in the Taxus group compared to 0.33% in the Xience V group (p=0.002).

In the two-year followup of the COMPARE trial, which included nearly 1800 patients, Peter Smits reported that the rate of death, nonfatal MI, and TVR was 13.7% in the Taxus group compared to 9.0% in the Xience group (p=0.0016). Definite or probable stent thrombosis was 3.9% in the Taxus group compared to 0.9% in the Xience group (p<0.0001).

The American College of Cardiology (ACC) will be a co-sponsor of the TCT Symposium in 2011, the ACC and the Cardiovascular Research Foundation (CRF) announced on Thursday. The arrangement will deepen the existing relationship between the two organizations, which already collaborate on the Innovations in Interventions (i2) Summit at ACC’s Annual Scientific Sessions.

In a blog post, incoming ACC president David Holmes wrote:

“Today’s announcement means the two groups will work together on a partnership that involves sharing content and distribution of educational materials. The ACC and CRF will form a physician-led ‘Collaborative Council’ of senior physician leaders that will meet regularly to review progress towards established objectives and to set the strategic direction of the affiliation. ACC and CRF staff will also meet regularly to share best practices, consider joint procurement of vendors, consider reciprocal exposition space at annual meetings, and explore collaboration around industry training programs.”

This post is republished with permission from CardioExchange, a new website for cardiovascular healthcare professionals from the New England Journal of Medicine. CardioBrief readers who are healthcare professionals are invited to join the site.

Leave a Reply

%d bloggers like this: